Clinical Trials Browser

INDUSTRY × Breast Neoplasms × pertuzumab × Clear all

NCT05132582 2026-03-16

HER2CLIMB-05

Phase 3 Active not recruiting

Breast Neoplasms

NCT07102381 2026-03-12

EmpowHER 208

Phase 2 Recruiting

Breast Neoplasms

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT06686394 2026-02-13

MK-1022-009

Phase 1/2 Recruiting

Breast Neoplasms

NCT04158258 2026-02-12

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Active not recruiting

Breast Neoplasms

NCT05415215 2026-02-10

ProHer

Phase 3 Completed

346 enrolled 20 charts

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT07386938 2026-02-04

A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

Breast Neoplasms

NCT05296798 2026-01-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Phase 3 Active not recruiting

Breast Neoplasms

NCT07294508 2025-12-29

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT07294534 2025-12-19

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT04538742 2025-12-08

DB-07

Phase 1/2 Active not recruiting

Brain Neoplasms, Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT04514419 2025-11-21

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Phase 3 Active not recruiting

Breast Neoplasms

NCT05954143 2025-11-20

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Phase 2 Terminated

11 enrolled 13 charts

Breast Neoplasms

NCT06884254 2025-10-14

EGC102

Phase 3 Withdrawn

Breast Neoplasms

NCT06178159 2025-10-01

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05802225 2025-07-20

PREFER

Phase 3 Active not recruiting

Breast Neoplasms

NCT04188548 2025-06-04

EMBER

Phase 1 Active not recruiting

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT05838066 2025-05-30

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

Phase 3 Recruiting

Breast Neoplasms

NCT03726879 2024-11-05

IMpassion050

Phase 3 Completed

454 enrolled 28 charts

Breast Neoplasms

NCT05283837 2024-07-18

A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

Phase 3 Completed

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

Phase 3 Completed

500 enrolled 28 charts 2 FDA

Breast Neoplasms

NCT04629846 2024-04-19

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Phase 3 Completed

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

Phase 2 Completed

Breast Neoplasms

NCT01120184 2024-03-04

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Phase 3 Completed

1,095 enrolled 46 charts

Breast Neoplasms

NCT02586025 2023-05-22

PEONY

Phase 3 Completed

329 enrolled 33 charts

Breast Neoplasms

NCT05738993 2023-02-22

A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers

Phase 1 Unknown

Breast Neoplasms

NCT05471648 2023-01-26

A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers

Phase 1 Completed

Breast Neoplasms

NCT02229149 2022-12-02

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms

NCT02896855 2021-12-16

PUFFIN

Phase 3 Completed

243 enrolled 23 charts

Breast Neoplasms

NCT02536339 2021-12-07

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

Phase 2 Completed

40 enrolled 34 charts

Breast Neoplasms

NCT02266173 2021-05-03

Observational Study of Pertuzumab Safety in Participants With Breast Cancer

Breast Neoplasms

NCT01491737 2020-10-28

PERTAIN

Phase 2 Completed

258 enrolled 18 charts

Breast Neoplasms

NCT01572038 2020-09-25

PERUSE

Phase 3 Completed

1,436 enrolled 53 charts

Breast Neoplasms

NCT02605915 2020-02-05

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT02445586 2019-10-29

Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer

Phase 4 Completed

52 enrolled 41 charts

Breast Neoplasms

NCT02402712 2019-09-06

Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00833963 2019-05-16

MotHER

Breast Neoplasms

NCT02019277 2018-09-13

SAPPHIRE

Phase 3 Completed

50 enrolled 18 charts

Breast Neoplasms

NCT01026142 2018-08-14

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Phase 3 Completed

452 enrolled 18 charts

Breast Neoplasms

NCT01501487 2018-06-28

MINT

Phase 4 Completed

Breast Neoplasms

NCT02738970 2018-06-12

A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

Phase 1 Completed

Breast Neoplasms

NCT01918254 2017-09-12

A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein

Phase 1 Completed

Breast Neoplasms

NCT00545688 2017-08-15

A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Phase 2 Completed

417 enrolled 25 charts

Breast Neoplasms

NCT00934856 2017-04-06

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Phase 1/2 Completed

98 enrolled 40 charts

Breast Neoplasms

NCT00976989 2017-02-06

A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

Phase 2 Completed

225 enrolled 19 charts

Breast Neoplasms

NCT01565083 2016-11-22

VELVET

Phase 2 Completed

213 enrolled 14 charts

Breast Neoplasms